Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cell and Gene Therapy CRO Market Review Report 2024-2031 | Latest by InsightAce Analytic Pvt. Ltd.

This image opens in the lightbox

News provided by

InsightAce Analytic Pvt. Ltd

10 Jun, 2024, 14:01 GMT

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., June 10, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy CRO Market- (By Type of Cell Therapy (CAR-NK, CAR-T, TCR-T, and Others), By Type of Genetic Modification (Ex vivo and In vivo), By Stage of Development (Discovery, Preclinical, and Clinical)), By Therapeutic Area, By End-user, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Cell and Gene Therapy CRO Market is valued at US$ 1.46 Bn in 2023, and it is expected to reach US$ 2.43 Bn by 2031, with a CAGR of 6.7% during the forecast period of 2024-2031.

Gene therapies are a type of medicine that has the potential to treat many different ailments. Whereas conventional medicine focuses on alleviating symptoms, their strategy is to deal with the sources of ailments. Also, they have the potential to help with a wide variety of ailments that have not responded to other treatments, including those involving the eyes, the nervous system, and cancer. One approach to gene therapy that makes use of viral vectors is the delivery of therapeutic genes to cardiac or arterial cells.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2521 

Some cardiovascular illnesses, such as heart failure and hereditary heart issues, have demonstrated some improvement in response to gene therapy, according to various clinical trials. Finally, gene therapy research and development are attracting increasing interest from both the public and corporate sectors. Consequently, cell and gene therapy for coronary artery disease is expected to see an expansion in the market in the years ahead. However, the poor retention of skilled manpower is a limitation on the worldwide cell and gene therapy CRO market's growth, making it one of the most difficult markets to maintain a stable workforce.

List of Prominent Players in the Cell and Gene Therapy CRO Market:

  • Altasciences
  • Allucent
  • CMIC
  • Labcorp
  • Linical
  • Medpace
  • PPD
  • Precision for Medicine
  • QPS
  • Syneos Health
  • CMED
  • ICON
  • Pharmalex
  • Novotech

Cell and Gene Therapy CRO Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 1.46 Bn

Revenue Forecast In 2031

USD 2.43 Bn

Growth Rate CAGR

CAGR of 6.7% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type of Cell Therapy, By Stage of Development, By Type of Genetic Modification, By Therapeutic Area, By End-users and By Region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea

Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2521 

Market Dynamics:

Drivers:

The growing demand for cell and gene therapy in the cardiovascular disease market is fueled by the rising incidence of long-term illnesses, such as cancer and rare genetic disorders impacting numerous unusual diseases. An increasing number of people are recognizing gene therapy as a viable option for cancer treatment, and the growing number of governments backing this field are all elements propelling the market forward.

Challenges:

The prime challenges are high investment, a shortage of competent individuals, and a lack of norms and protocol because of lockdowns and isolation in emerging countries, which is predicted to slow the growth of the cell and gene therapy CRO market. Producing and delivering gene therapies can be highly costly due to the fact that gene therapy is a relatively new and advanced medical technology. Since these costs are often passed on to patients, many individuals, particularly those without adequate insurance or financial means, are unable to afford them. There are no clear payment standards, and insurance options are few, which contributes to the exorbitant expense of therapy.

Insurance companies and healthcare providers may be hesitant to fund the costs of gene treatments, especially for rare diseases or disorders, due to the lack of information on their long-term safety and effectiveness. This has the potential to slow the expansion of cell and gene therapy and make it more difficult for patients to get these treatments. The COVID-19 pandemic has had a major effect on the healthcare industry as a whole, plus the gene therapy industry, specifically in relation to cardiovascular disease. Site limitations, closures, and disruptions to the supply chain all contributed to the pandemic's strong influence on clinical trials.

Regional Trends:

The North American gene therapy in the cell and gene therapy CRO market is anticipated to register a major market share in terms of revenue. It is projected to grow at a high CAGR in the near future because of the rising number of cases of cardiovascular disease, massive investments in R&D, novel technologies, new government programs, and growing healthcare costs.

Besides, Europe had a substantial share in the market because of many things, including a larger patient population in the sector, more infectious illness cases, more people knowing about gene therapy, more cancer cases, and more people involved in research and development.

Curious about this latest version of the report? @https://www.insightaceanalytic.com/enquiry-before-buying/2521 

Recent Developments:

  • In January 2024, ICON plc announced that Chief Financial Officer Brendan Brennan would resign in the final period of this year to pursue an adventure within the CRO field. To facilitate a seamless transfer to the new Chief Financial Officer, Brendan will continue in his current position and join the firm. A hunt for ICON's next chief financial officer has begun.
  • In March 2024, Novotech announced that the Commission for Drugs for Humans of the European Medicines Agency (EMA) has recommended that Fabhalta (iptacopan) be approved for marketing to treat adulthood with nocturnal paroxysms of hemoglobin (PNH) and hemolytic anemia.

Segmentation of Cell and Gene Therapy CRO Market

By Type of Cell Therapy

  • CAR-NK
  • CAR-T
  • TCR-T
  • Others

By Type of Genetic Modification

  • Ex vivo
  • In vivo

By Stage of Development

  • Discovery
  • Preclinical
  • Clinical

By Therapeutic Area

  • Blood Disorders
  • Cardiovascular Disorders
  • Dermatological Disorders
  • Immunological Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Rare Diseases
  • Other disorders

Cell and Gene Therapy CRO Market-By End-Users

  • Industry Players
  • Non-Industry Players

Cell and Gene Therapy CRO Market-By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2521

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for global Cell and Gene Therapy CRO market
  • To receive industry overview and future trends of global Cell and Gene Therapy CRO market
  • To analyze the Cell and Gene Therapy CRO market drivers and challenges
  • To get information on the Cell and Gene Therapy CRO market size value (US$ Mn) forecast till 2031
  • Major Investments, Mergers & Acquisition in global Cell and Gene Therapy CRO industry

Other Related Reports Published by InsightAce Analytic:

Lipid Nanoparticles (LNPs) CDMO Market

Advanced Drug Delivery CDMO Market 

Radiopharmaceutical CDMO/CMO Services Market

Advanced Drug Delivery CDMO Market

Nucleic Acid Therapeutics CDMO Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/ 

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

Modal title

Also from this source

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Functional Service Providers (FSP) Market- (By...

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Sustainable Beauty and Skincare Market'- By Type (Organic...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.